Tenaya Therapeutics, Inc.

TNYASEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1858848

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$86.7M	$98.0M	$94.5M	$54.4M	$31.1M
Operating Expenses	$115.9M	$131.2M	$125.6M	$72.8M	$38.9M
Operating Income (Loss)	-$115.9M	-$131.2M	-$125.6M	-$72.8M	-$38.9M
Nonoperating Income (Expense)	$4.8M	$7.1M	$2.0M	$85.0K	$517.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$111.1M	-$124.1M	-$123.7M	-$72.7M	-$38.4M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$111.1M	-$124.1M	-$123.7M	-$72.7M	-$38.4M
Earnings Per Share, Basic	-$1.31	-$1.68	-$2.76	-$4.10	—
Earnings Per Share, Diluted	-$1.31	-$1.68	-$2.76	-$4.10	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$119.9M	$170.5M	$278.9M	$314.2M	$148.2M
Assets, Current	$67.4M	$111.6M	$193.8M	$255.4M	$130.0M
Cash and Cash Equivalents, at Carrying Value	$4.3M	$45.7M	$95.3M	$38.1M	$128.5M
Liabilities	$27.1M	$31.1M	$35.6M	$35.7M	$8.7M
Liabilities, Current	$16.0M	$22.7M	$24.2M	$21.8M	$5.0M
Accounts Payable, Current	$5.2M	$5.6M	$9.6M	$10.7M	$1.0M
Stockholders' Equity Attributable to Parent	$139.4M	$243.4M	$278.5M	-$81.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$90.5M	-$102.1M	-$104.4M	-$60.8M	-$35.4M
Net Cash Provided by (Used in) Investing Activities	$1.1M	$48.7M	$83.7M	-$238.6M	-$7.0M
Net Cash Provided by (Used in) Financing Activities	$47.7M	$4.0M	$77.8M	$209.0M	$147.3M
Payments to Acquire Property, Plant, and Equipment	$1.0M	$1.2M	$20.6M	$25.1M	$9.8M
Payments for Repurchase of Common Stock	—	—	—	$13.0K	$1.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)